# 2025-23717: DEA Schedules Two Potent Synthetic Opioids in Strictest Ban Category

2025-23717, Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I, is a Federal Register rule from Justice Department, Drug Enforcement Administration published 2025-12-23, effective 2026-01-22 (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-23717
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-23717
- Title: Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I
- Type: Rule
- Agencies: Justice Department; Drug Enforcement Administration
- Citation: 90 FR 59969
- Published: 2025-12-23
- Effective: 2026-01-22
- Comments close: not stated
- Significant: no
- Touches household money: no
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

DEA Schedules Two Potent Synthetic Opioids in Strictest Ban Category

## Summary

Starting January 22, 2026, two powerful drugs called N-desethyl isotonitazene and N-piperidinyl etonitazene will be officially banned and placed in the toughest drug category, Schedule I. This means anyone making, selling, or using these drugs will face serious legal trouble. This move helps the U.S. follow international drug rules and keeps communities safer without adding new costs.

## Abstract

With the issuance of this final order, the Administrator of the Drug Enforcement Administration is permanently placing N-ethyl-2- (2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name: N-desethyl isotonitazene) and 2-(4-ethoxybenzyl)-5-nitro- 1-(2-(piperidin-1-yl)ethyl)-1H-benzimidazole (other names: N- piperidinyl etonitazene; etonitazepipne), including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, and salts are possible within the specific chemical designation, in schedule I under the Controlled Substances Act. This scheduling action discharges the United States' obligations under the Single Convention on Narcotic Drugs (1961). This action imposes permanent regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research or conduct instructional activities with or possess), or handle N-desethyl isotonitazene and N-piperidinyl etonitazene.

## Effects PRIA read

- Manufacturers and Distributors Face Schedule I Controls: cost, medium. Starting January 22, 2026, manufacturers, distributors, importers, and exporters of N-desethyl isotonitazene and N-piperidinyl etonitazene must be registered with the DEA and follow Schedule I rules. That includes following 21 U.S.C. registration and quota rules, keeping inventories (initial invent…
- Researchers and Instructional Users Must Register: cost, medium. From January 22, 2026, anyone who engages in research or instructional activities with these two substances must register with DEA and follow Schedule I requirements such as security screening, labeling and packaging rules, disposal under 21 CFR part 1317, and recordkeeping and reporting obligation…
- Possession or Retail Sales Will Be Unlawful: cost, medium. Effective January 22, 2026, possession of any quantity of N-desethyl isotonitazene or N-piperidinyl etonitazene without DEA authorization is unlawful and may lead to prosecution, and retail sales of Schedule I substances to the general public are not allowed under the Controlled Substances Act. Una…

## Related documents

- [2026-11526](https://policyrisk.com/federal-register/2026-11526): Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 201…, 2026-06-09
- [2026-10128](https://policyrisk.com/federal-register/2026-10128): Revision of Applications for Manufacturing and Procurement Quotas, 2026-05-20
- [2025-05007](https://policyrisk.com/federal-register/2025-05007): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-03-24
- [2025-02793](https://policyrisk.com/federal-register/2025-02793): Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients, 2025-02-19
- [2026-22843](https://policyrisk.com/federal-register/2026-22843): Proposed Aggregate Production Quotas for Schedule I and II Controlled Substances and Assessment of Annual Needs for the List I Chemicals Ep…, 2026-11-10
- [2026-22842](https://policyrisk.com/federal-register/2026-22842): Adjustment to the 2026 Aggregate Production Quota for d,l-Amphetamine, d-Amphetamine (for Sale), Hydromorphone and Methylphenidate (for Sal…, 2026-11-10

## Sources
- [2025-23717 on federalregister.gov](https://www.federalregister.gov/documents/2025/12/23/2025-23717/schedules-of-controlled-substances-placement-of-n-desethyl-isotonitazene-and-n-piperidinyl)
- [2025-23717 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-12-23/pdf/2025-23717.pdf)

## Related
- [Previous: 2025-23685, Safety Zone; West of Cyril E. King Airport, St. Thomas, VI](https://policyrisk.com/federal-register/2025-23685)
- [Next: 2025-23738, Amendment of Colored Federal Airway Green 8, Jet Route J-115, United States Are…](https://policyrisk.com/federal-register/2025-23738)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-23717 (as of 2026-06-11).
